Risk of respiratory diseases among hospitalized patients with hidradenitis suppurativa.

Publisher: Blackwell Science Country of Publication: England NLM ID: 0243704 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-4632 (Electronic) Linking ISSN: 00119059 NLM ISO Abbreviation: Int J Dermatol Subsets: MEDLINE

Publication: Oxford : Blackwell Science
Original Publication: Philadelphia, Lippincott.

Hidradenitis Suppurativa*/epidemiology ; Hidradenitis Suppurativa*/complications ; Asthma*/epidemiology ; Asthma*/complications ; Hospitalization*/statistics & numerical data; Humans ; Female ; Male ; Case-Control Studies ; Cross-Sectional Studies ; Adult ; Middle Aged ; United States/epidemiology ; Risk Factors ; Sarcoidosis/epidemiology ; Sarcoidosis/complications ; Sleep Apnea Syndromes/epidemiology ; Sleep Apnea Syndromes/complications ; Young Adult ; Comorbidity ; Aged ; Respiratory Tract Diseases/epidemiology ; Adolescent

Background: Hidradenitis suppurativa (HS) is a systemic disorder associated with various metabolic and inflammatory comorbidities. Although HS shares risk factors and pathogenic pathways with various respiratory conditions, few studies have explored the relationship between HS and respiratory disease.
Methods: This is a cross-sectional, case-control, population-based study that examined the United States National Inpatient Sample database from January 1, 2002, to December 31, 2012. HS was identified using ICD-9-CM codes during hospital admissions. Multivariable logistic regression was used to evaluate for adjusted associations between HS and respiratory diagnoses as compared to matched controls.
Results: Twenty-three thousand seven hundred and sixty-seven hospital admissions for HS were compared with 95,068 age- and sex-matched controls. HS patients had significantly higher adjusted odds of asthma (OR: 1.233; 95% CI: [1.170-1.299]; P < 0.001), chronic airway obstruction (OR: 1.532; 95% CI: [1.419-1.651]; P < 0.001), sarcoidosis (OR: 1.601; 95% CI: [1.157-2.214]; P < 0.001), and sleep apnea (OR: 1.274; 95% CI: [1.182-1.374]; P < 0.001).
Conclusion: HS is associated with several common forms of respiratory disease. Knowledge of these associations may allow for better recognition of respiratory disease in HS patients.
(© 2024 The Authors. International Journal of Dermatology published by Wiley Periodicals LLC on behalf of the International Society of Dermatology.)

Lee EY, Alhusayen R, Lansang P, Shear N, Yeung J. What is hidradenitis suppurativa? Can Fam Physician. 2017;63(2):114–120.
Danby FW, Margesson LJ. Hidradenitis suppurativa. Dermatol Clin. 2010;28(4):779–793. https://doi.org/10.1016/j.det.2010.07.003.
Jemec GB. Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012;366(2):158–164. https://doi.org/10.1056/NEJMcp1014163.
Vossen ARJV, van der Zee HH, Prens EP. Hidradenitis suppurativa: a systematic review integrating inflammatory pathways into a cohesive pathogenic model. Front Immunol. 2018;9:2965. https://doi.org/10.3389/fimmu.2018.02965.
Kelly G, Sweeney CM, Tobin AM, Kirby B. Hidradenitis suppurativa: the role of immune dysregulation. Int J Dermatol. 2014;53(10):1186–1196. https://doi.org/10.1111/ijd.12550.
Saunte D, Jemec G. Hidradenitis suppurativa: advances in diagnosis and treatment. JAMA. 2017;318(20):2019–2032. https://doi.org/10.1001/jama.2017.16691.
Nguyen TV, Damiani G, Orenstein L, Hamzavi I, Jemec GB. Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. J Eur Acad Dermatol Venereol. 2021;35(1):50–61. https://doi.org/10.1111/jdv.16677.
Sabat R, Jemec G, Matusiak Ł, Kimball AB, Prens E, Wolk K. Hidradenitis suppurativa. Nat Rev Dis Primers. 2020;6(1):18. https://doi.org/10.1038/s41572‐020‐0149‐1.
Zouboulis CC, Benhadou F, Byrd AS, Chandran NS, Giamarellos‐Bourboulis EJ, Fabbrocini G, et al. What causes hidradenitis suppurativa? 15 years after. Exp Dermatol. 2020;29(12):1154–1170. https://doi.org/10.1111/exd.14214.
Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475. https://doi.org/10.3390/ijms20061475.
Oliveira M, Rocha B, Duarte GV. Psoriasis: classical and emerging comorbidities. An Bras Dermatol. 2015;90(1):9–20. https://doi.org/10.1590/abd1806‐4841.20153038.
Dreiher J, Weitzman D, Shapiro J, Davidovici B, Cohen AD. Psoriasis and chronic obstructive pulmonary disease: a case‐control study. Br J Dermatol. 2008;159(4):956–960. https://doi.org/10.1111/j.1365‐2133.2008.08749.x.
Maverakis E, Marzano AV, Le ST, Callen JP, Brüggen MC, Guenova E, et al. Pyoderma gangrenosum. Nat Rev Dis Primers. 2020;6(1):81. https://doi.org/10.1038/s41572‐020‐0213‐x.
Ashchyan HJ, Butler DC, Nelson CA, Noe MH, Tsiaras WG, Lockwood SJ, et al. The association of age with clinical presentation and comorbidities of pyoderma gangrenosum. JAMA Dermatol. 2018;154(4):409–413. https://doi.org/10.1001/jamadermatol.2017.5978.
Gade M, Studstrup F, Andersen AK, Hilberg O, Fogh C, Bendstrup E. Pulmonary manifestations of pyoderma gangrenosum: 2 cases and a review of the literature. Respir Med. 2015;109(4):443–450. https://doi.org/10.1016/j.rmed.2014.12.016.
López‐Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology. 2016;21(1):14–23. https://doi.org/10.1111/resp.12660.
GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability‐adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691–706. https://doi.org/10.1016/S2213‐2600(17)30293‐X.
Wertenteil S, Strunk A, Garg A. Incidence of obstructive sleep apnoea in patients with hidradenitis suppurativa: a retrospective population‐based cohort analysis. Br J Dermatol. 2018;179(6):1398–1399. https://doi.org/10.1111/bjd.16931.
Seltzer JA, Okeke C, Perry JD, Shipman WD, Okoye GA, Byrd AS. Exploring the risk of severe COVID‐19 infection in patients with hidradenitis suppurativa. J Am Acad Dermatol. 2020;83(2):e153–e154. https://doi.org/10.1016/j.jaad.2020.05.012.
Netzer NC, Stoohs RA, Netzer CM, Clark K, Strohl KP. Using the Berlin Questionnaire to identify patients at risk for the sleep apnea syndrome. Ann Intern Med. 1999;131(7):485–491. https://doi.org/10.7326/0003‐4819‐131‐7‐199910050‐00002.
Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007;370(9589):765–773. https://doi.org/10.1016/S0140‐6736(07)61380‐4.
Osei ET, Brandsma CA, Timens W, Heijink IH, Hackett TL. Current perspectives on the role of interleukin‐1 signalling in the pathogenesis of asthma and COPD. Eur Respir J. 2020;55(2):1900563. https://doi.org/10.1183/13993003.00563‐2019.
Rosi E, Fastame MT, Scandagli I, Di Cesare A, Ricceri F, Pimpinelli N, et al. Insights into the pathogenesis of HS and therapeutical approaches. Biomedicine. 2021;9(9):1168. https://doi.org/10.3390/biomedicines9091168.
Kjærsgaard Andersen R, Jørgensen IF, Reguant R, Jemec G, Brunak S. Disease trajectories for hidradenitis suppurativa in the danish population. JAMA Dermatol. 2020;156(7):780–786. https://doi.org/10.1001/jamadermatol.2020.1281.
Garg A, Malviya N, Strunk A, Wright S, Alavi A, Alhusayen R, et al. Comorbidity screening in hidradenitis suppurativa: evidence‐based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. J Am Acad Dermatol. 2022;86(5):1092–1101. https://doi.org/10.1016/j.jaad.2021.01.059.
Strunk A, Midura M, Papagermanos V, Alloo A, Garg A. Validation of a case‐finding algorithm for hidradenitis suppurativa using administrative coding from a clinical database. Dermatology. 2017;233(1):53–57. https://doi.org/10.1159/000468148.
Ferrante G, La Grutta S. The burden of pediatric asthma. Front Pediatr. 2018;6:186. https://doi.org/10.3389/fped.2018.00186.
Benjafield AV, Ayas NT, Eastwood PR, Heinzer R, Ip M, Morrell MJ, et al. Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature‐based analysis. Lancet Respir Med. 2019;7(8):687–698. https://doi.org/10.1016/S2213‐2600(19)30198‐5.
Seivright JR, Collier E, Grogan T, Hogeling M, Shi VY, Hsiao JL. Physical and psychosocial comorbidities of pediatric hidradenitis suppurativa: a retrospective analysis. Pediatr Dermatol. 2021;38(5):1132–1136. https://doi.org/10.1111/pde.14765.
Campione E, Lanna C, Diluvio L, Cannizzaro MV, Grelli S, Galluzzo M, et al. Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo. Cell Cycle. 2020;19(3):257–267. https://doi.org/10.1080/15384101.2019.1707455.
Busse WW. Asthma and psoriasis: what do they have in common? IL‐17A! J Allergy Clin Immunol. 2019;144(5):1169–1171. https://doi.org/10.1016/j.jaci.2019.09.006.
Müller‐Quernheim J, Prasse A, Zissel G. Pathogenesis of sarcoidosis. Presse Med. 2012;41(6 Pt 2):e275–e287. https://doi.org/10.1016/j.lpm.2012.03.018.
Ezzie ME, Crouser ED. Considering an infectious etiology of sarcoidosis. Clin Dermatol. 2007;25(3):259–266. https://doi.org/10.1016/j.clindermatol.2007.03.003.
Lee HH, Patel KR, Singam V, Rastogi S, Silverberg JI. Associations of cutaneous and extracutaneous infections with hidradenitis suppurativa in U.S. children and adults. Br J Dermatol. 2020;182(2):327–334. https://doi.org/10.1111/bjd.18093.
Chiang CL, Chen YT, Wang KL, Su VY, Wu LA, Perng DW, et al. Comorbidities and risk of mortality in patients with sleep apnea. Ann Med. 2017;49(5):377–383. https://doi.org/10.1080/07853890.2017.1282167.
Ioannidou D, Kalamaras G, Kotoulas SC, Pataka A. Smoking and obstructive sleep apnea: is there an association between these cardiometabolic risk factors? Gender analysis. Medicina (Kaunas). 2021;57(11):1137. doi:10.3390/medicina57111137.
Hua VJ, Kilgour JM, Cho HG, Li S, Sarin KY. Characterization of comorbidity heterogeneity among 13,667 patients with hidradenitis suppurativa. JCI Insight. 2021;6(21):e151872. https://doi.org/10.1172/jci.insight.151872.
Hirotsu C, Nogueira H, Albuquerque RG, Tomimori J, Tufik S, Andersen ML. The bidirectional interactions between psoriasis and obstructive sleep apnea. Int J Dermatol. 2015;54(12):1352–1358. https://doi.org/10.1111/ijd.13026.
Cartron A, Driscoll MS. Comorbidities of hidradenitis suppurativa: a review of the literature. Int J Womens Dermatol. 2019;5(5):330–334. https://doi.org/10.1016/j.ijwd.2019.06.026.
Jørgensen AR, Yao Y, Ghazanfar MN, Ring HC, Thomsen SF. Burden, predictors and temporal relationships of comorbidities in patients with hidradenitis suppurativa: a hospital‐based cohort study. J Eur Acad Dermatol Venereol. 2020;34(3):565–573. https://doi.org/10.1111/jdv.15904.
Reddy S, Strunk A, Garg A. Comparative overall comorbidity burden among patients with hidradenitis suppurativa. JAMA Dermatol. 2019;155(7):797–802. https://doi.org/10.1001/jamadermatol.2019.0164.
Kelly A, Meurling J, Kirthi Jeyarajah S, Ryan C, Hughes R, Garvey J, et al. Obstructive sleep apnoea in psoriasis and hidradenitis suppurativa. Br J Dermatol. 2021;184(6):1183–1185. https://doi.org/10.1111/bjd.19802.
Lima XT, Cueva MA, Alora MB. COVID‐19 in patients with hidradenitis suppurativa. Br J Dermatol. 2021;184(1):182–184. https://doi.org/10.1111/bjd.19492.
Naik HB, Alhusayen R, Frew J, Guilbault S, Hills NK, Ingram JR, et al. Biologic therapy is not associated with increased COVID‐19 severity in patients with hidradenitis suppurativa: initial findings from the Global Hidradenitis Suppurativa COVID‐19 Registry. J Am Acad Dermatol. 2022 Jan 1;86(1):249–252. https://doi.org/10.1016/j.jaad.2021.09.016.
Khan S, Karponis D, Wali G. Outcomes of patients with chronic plaque psoriasis and hidradenitis suppurativa on biologic therapy during the Covid‐19 pandemic: a UK dermatology tertiary centre experience. Skin Health Dis. 2021;1:e54. https://doi.org/10.1002/ski2.54.
Dewigne M, Orte Cano C, Daoud M, Del Marmol V, Benhadou F. Low incidence of COVID‐19 in hidradenitis suppurativa: how to interpret it? Exp Dermatol. 2022;31(3):435–436. https://doi.org/10.1111/exd.14475.
Rozzo G, Ramondetta A, Fierro MT, Dapavo P, Ribero S. Moderate‐to‐severe hidradenitis suppurativa under systemic therapy during the COVID‐19 outbreak. Dermatol Ther. 2020;33(4):e13680. https://doi.org/10.1111/dth.13680.
Di Alberti L, Piattelli A, Artese L, Favia G, Porter SR, Scully CM, et al. Human herpesvirus 8 variants in sarcoid tissues. Lancet. 1997;350(9092):1655–1661. https://doi.org/10.1016/s0140‐6736(97)10102‐7.
Gau SY, Chan WL, Tsai JD. Risk of atopic diseases in patients with hidradenitis suppurativa: a systematic review and meta‐analysis of observational studies. Dermatology. 2023;239(2):314–322. https://doi.org/10.1159/000528920.
Yeroushalmi S, Ildardashty A, Elhage KG, Chung M, Bartholomew E, Hakimi M, et al. Hidradenitis suppurativa and sleep: a systematic review. Arch Dermatol Res. 2023;315(5):1409–1415. https://doi.org/10.1007/s00403‐022‐02460‐x.

Keywords: acne inversa; asthma; chronic obstructive pulmonary disease; comorbidity; hidradenitis suppurativa; respiratory diseases; sleep apnea

Date Created: 20240418 Date Completed: 20241019 Latest Revision: 20241019

20241020

10.1111/ijd.17182

38634645